INVO BioScience, Inc.

Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star then two. Please note today's event is being recorded. I would now like to turn the conference over to Robert Bloom with Lithum Partners. Please go ahead.

Thank you so much. Good afternoon, everyone. And as Rocco indicated, thank you for joining us for today's INVO first quarter 2023 financial results conference call. Joining us on the call today are INVO's CEO, Steve Shum, the company's chief operating officer and VP of business development, Mike Campbell, and Andrea Gorin, the company's chief financial officer. At the conclusion of today's prepared remarks, we'll open the call for a question and answer session. Before we begin with the event, we submit for the record the following statements. Certain matters discussed on this conference call by the management of InvoBioscience may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, Section 21E of the Securities Exchange Act of 1934 as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. all statements regarding the company's expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as anticipate, if, believe, plan, estimate, expect, intend, may, could, should, will, and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond the company's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in the company's filings at www.sec.gov. The company is under no obligation to and expressly disclaims any such obligation to update or alter our forward-looking statements, whether as the result of new information, future events, or otherwise. With that said, let me turn the call over to Steve Shum, Chief Executive Officer of Invo. Steve, please proceed.

Thank you, Robert, and welcome, everyone. As many of you know, we held our year-end call recently, just four weeks ago, where we covered a number of important updates. For this call, we plan to keep our prepared remarks shorter and highlight the specific quarter developments as well as reiterate some of the key items covered in the last call. In the first quarter, our three existing INVO centers in Birmingham, Atlanta, and Monterey all made further progress, reaching new levels. On a combined basis, inclusive of both those accounted for as consolidated and under the equity method, the centers generated approximately 647,000 for the first quarter, an increase of 108% from the year-ago quarter, and an impressive 46% increase sequentially from the most recent fourth quarter. We believe they will continue the positive upward trend over the rest of this year. Another key point to make is that the three existing clinics are nearing break-even, and we look forward to each of them generating positive cash flows and profits in the near future. As we mentioned on our recent year-end call, our planned new InvoCenter in Tampa is progressing with a target opening slated for mid-summer this year. We are excited about Tampa. We believe we have assembled an excellent team to operate the practice, and they are well into the training. and planning phases in preparation for the opening. The Tampa market is large and attractive and we are looking forward to bringing the center operational. We have begun early preparation work for Kansas City and remain very excited about the potential partnering we expect to do for that market and look forward to providing updates on this location in the near future. We have decided to put the previously mentioned Bay Area clinic opportunity on hold for now both ourselves and our partner mutually agreed this made sense as we are both focused on other key priorities right now for us as many of you know a key new priority revolves around our acquisition strategy and specifically our announced agreement to acquire the wisconsin fertility institute we spent a fair amount of time discussing the transaction and our acquisition approach on our last call but I do want to mention a few key highlights as a reminder. We believe the acquisition strategy enhances our commercial efforts to build the company and is an activity where we can synergistically introduce InvoCell into existing IVF clinics that we take ownership of. This effort will remain focused on existing, established, and profitable clinics. Our first deal, the clinic located in Wisconsin has an excellent reputation, not only in the local community, but nationally is one of the top fertility centers in America. It is, it is well run and profitable. We issued an AK regarding the transaction, which provided two years of audited financials, along with the nine months review for the clinic. And we then reflected those financials on a pro forma basis, as if it had been part of Invo's operations during that historical period. As reflected in those numbers, the clinic produces excellent results with about 5.5 million in trailing revenue and around 1.9 million in net income, a very material addition to our operations on a go-forward basis. As we've mentioned previously, our acquisition efforts are strategically significant for several reasons. It provides immediate revenue and positive net income to our overall operations, adding scale and accelerating our pathway to overall profitability. It highlights our efforts to use our public company status as a platform to take a more comprehensive approach within the fertility marketplace. Although we are now becoming, through this activity, a broader fertility company in general, acquisitions do still help further one of our key longstanding goals of advancing the InvoCell technology and the IVC treatment method. We will look to integrate our solution into acquired practices and help to drive new additive revenue and profits in addition to the existing conventional IVF business these established clinics are already providing. This provides another pathway to further our efforts to bring added affordable care to the marketplace and help patients in need. Again, we are focused on smaller to mid-sized established fertility practices in the marketplace with these acquisition efforts. We do have several discussions ongoing, and we'll focus on pricing deals attractively and structuring them in a win-win manner similar to Wisconsin. To summarize, our expanded commercial strategy now includes supporting, servicing, and expanding InvoCell across existing IVF clinics building new dedicated info centers, and now selectively acquiring existing IVF practices. As noted on our recent call, we've also made significant progress with our five-day label enhancement efforts. We completed tabulating the additional data related to the follow-up questions from FDA and are submitting those at the end of this week. We believe the data, including the additional tabulations, looks very good and we are very pleased with the outcomes and excited to share those with the market as soon as possible. Let me turn this over to Andrea to quickly cover additional financial highlights. Andrea?